FDA Extends the DSCSA Small-Business-Dispenser Exemption to November 27, 2027

FDA's Center for Drug Evaluation and Research issued an exemption letter on 6 August 2026 extending, for a further year, specified relief from the Drug Supply Chain Security Act's enhanced drug distribution security requirements for qualifying small business dispensers and, where the letter says so, their trading partners. The letter states that FDA "is using authority under section 582(a)(3) of the Food, Drug, and Cosmetic Act (FD&C Act) to grant exemptions." It is not a regulation and not a statement of enforcement discretion. It is an exercise of a statutory exemption power, communicated by posting on FDA's website, which the letter notes is consistent with FDA's August 2023 guidance on waivers, exceptions and exemptions.

The extension does not reach every dispenser, and it does not suspend every duty of the dispensers it does reach. This briefing works through who qualifies, which requirements are lifted and which remain in force throughout the exemption period, what relief preceded this letter, and the reasons FDA gives for granting it.

The letter sets out FDA's authority and its reasons. No separate regulatory impact analysis was identified in the sources reviewed for this briefing, and this briefing draws the distinction between what the letter changes and what it does not from the letter itself and from FDA's own pages, rather than from an analysis document.

The letter states that FDA "continues to define a dispenser as a small business dispenser if the corporate entity that owns the dispenser has a total of 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians," counted "as of November 27, 2026." Full-time employee carries a borrowed meaning: the letter states that "for the purpose of these exemptions, we are adopting the Internal Revenue Service's (IRS) definition of 'full-time employee,'" which is "for a calendar month, an employee employed on average at least 30 hours of service per week, or 130 hours of service per month." The counting date and the test for full-time status are separate questions, so full-time status is not established by hours worked on 27 November itself. The threshold applies at the level of the corporate entity that owns the dispenser, not at the level of an individual pharmacy.

Relief is not confined to the dispenser in every instance. The letter grants exemptions to small business dispensers and, where it says so, to their trading partners, and the covered party varies by provision. Under the saleable-returns provision, the letter states that "small business dispensers' trading partners may use current methods to accept saleable returns."

The exemptions cover the specified requirements of section 582(g)(1), cited individually at 582(g)(1)(A) through 582(g)(1)(F), which between them carry the interoperable electronic exchange of transaction information, package-level product identifiers, standardized verification systems, prompt response to recall and investigation requests, systems for gathering transaction information tracing back to the manufacturer, and acceptance of saleable returns.

Relief from section 582(d)(4) is considerably narrower than relief from 582(g)(1), and this is the point most easily lost. The exemptions reach two sub-provisions only, 582(d)(4)(A)(ii)(II) and 582(d)(4)(B)(iii), which concern verification of the product identifier for the statutorily specified proportion of suspect or illegitimate product in the dispenser's possession or control. The letter is explicit about the remainder: "small business dispensers are still obligated to meet all other verification requirements of section 582(d)(4) of the FD&C Act." A dispenser relying on this exemption is not relieved of suspect-product and illegitimate-product verification generally, and the duties outside those two sub-provisions apply during the exemption period rather than resuming at the end of it.

Nothing in the letter extends relief beyond the provisions it names. The letter also states what the exemptions are not for: "the exemptions described in this notification are not intended to provide, and should not be viewed as providing, a justification for delaying efforts by small business dispensers to implement the enhanced drug distribution security requirements."

The enhanced requirements predate this extension by some years, and the relief around them has come in stages. FDA's compliance policy on the stabilization period states that the period would "accommodate an additional year, until November 27, 2024, to allow trading partners to implement, troubleshoot and mature their electronic interoperable systems," covering manufacturers, wholesale distributors, dispensers and repackagers alike.

Relief did not stop there. A further exemption letter of 9 October 2024, DSCSA Exemptions from Section 582(g)(1) and Other Requirements of the FD&C Act for Certain Trading Partners, granted conditional exemptions to eligible trading partners on staggered timetables: manufacturers and repackagers until 27 May 2025, wholesale distributors until 27 August 2025, and dispensers with 26 or more full-time employees until 27 November 2025. Eligibility for those exemptions was conditional, reaching those who had initiated their systems and processes by completing data connections with their immediate trading partners, or who had documented efforts to do so without completing them with every immediate trading partner.

The transaction windows specified in that letter have ended, though the relief was written to attach to product rather than to a date alone: the dispenser exemption reached "any products transacted by eligible dispensers from November 27, 2024, until November 27, 2025," and the letter states that the exemptions "extend to trading partners throughout the pharmaceutical distribution supply chain who subsequently transact such product." Whether that letter still bears on a particular product or a downstream transaction has to be assessed against its own terms rather than assumed to have lapsed. FDA's exemptions page, read for this briefing, describes no current blanket exemption for dispensers outside the small business definition. A trading partner that does not qualify for a class exemption is left with the individual route: FDA's page on waivers and exemptions beyond the stabilization period states that trading partners "that do not qualify for the exemptions above and are unable to meet the enhanced drug distribution security requirements of section 582 of the FD&C Act, may request a waiver, exception or exemption from those requirements," and that "the agency expects the trading partner to continue their efforts to meet the requirements until FDA has approved or denied the request." A pending request is not stated on that page to pause or extend the underlying obligation.

The letter gives two reasons, one about the agency's own unfinished work and one about supply. On the first, it states that "there are still steps under section 582(g)(3) of the FD&C Act that are not yet completed as the current small business dispensers' compliance date of November 27, 2026 approaches." Section 582(g)(3) directs FDA to assess whether the technology small dispensers need is readily accessible, whether it is prohibitively expensive to obtain, install and maintain, and whether it can be integrated into their business practices, and to consider alternative methods of compliance in light of that assessment. On the second, the letter states that FDA "has determined that this extension is appropriate to maintain public health and help ensure continued patient access" to certain prescription drugs in the United States.

The assessment has been running for several years. FDA requested comment on its proposed scope through a Federal Register notice of 10 August 2023, and submitted the assessment's information collection for Office of Management and Budget review under the Paperwork Reduction Act through a notice of 21 November 2025. FDA's own assessment page states that it "is conducting the small dispensers assessment and will provide updates as appropriate," without giving a completion date. FDA encouraged small dispensers to complete the assessment survey by 22 September 2026, a date which has now passed; that date was an encouragement attached to a data-gathering exercise and not a compliance deadline, and whether the survey remains open was not established for this briefing. Nothing in the letter commits FDA to extending the exemption again after 27 November 2027.

Readiness checklist

The items in the checklist are drawn directly from the letter and the requirements it leaves in place. Items that are sound practice but not required follow separately below.

Good practice, not required by the letter

• Reliance on the exemption communicated to trading partners, which FDA recommends but does not require.
• Evidence of the 27 November 2026 headcount retained, for demonstrability. This is an OmniReg recommendation, not a recordkeeping condition the letter imposes.
• Implementation of the enhanced requirements continuing regardless of reliance on the exemption, consistent with FDA's statement that the exemptions are not a justification for delay.
• Compliance planning targeted to 27 November 2027, with no assumption that a further extension will follow.
• Where compliance cannot be achieved, a waiver, exception or exemption request prepared under section 582(a)(3) and directed to the correct FDA channel for the product type.
• Completion of the section 582(g)(3) assessment, the final assessment's publication for comment, and the public meeting, tracked as they occur, since FDA cites unfinished statutory steps as a basis for this extension.
• FDA announcements monitored for any eligibility criteria attached to future relief, assessed on their own terms.

Related FDA documents and resources

• DSCSA Exemptions from Certain Requirements Under Section 582 of the FD&C Act for Small Business Dispensers Until November 27, 2027 (6 August 2026, the instrument itself)
• DSCSA Exemptions from Section 582(g)(1) and Other Requirements of the FD&C Act for Certain Trading Partners (9 October 2024, the staggered, transaction-based exemptions)
• Waivers, Exceptions, and Exemptions from the Requirements of Section 582 of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry (final, August 2023)
• FDA's compliance policy on the one-year stabilization period
• FDA's Small Dispensers Assessment page, pending the assessment, its publication for comment, and the public meeting under section 582(g)(3)